Research & Clinical Trials

As the only national nonprofit advocacy organization focused on hereditary breast and ovarian cancer, FORCE has a strong commitment to promoting research.

| More

Research & Clinical Trials
Toggle Menu

NCT01434316

Veliparib and Dinaciclib With or Without Carboplatin in Treating Patients With Advanced Solid Tumors

Study identifier: NCT01434316
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Veliparib (Abbvie)

Eligibility:

  • Histologically confirmed diagnosis of a solid tumor for which no standard or curative therapy exists or for which standard therapy is no longer effective
  • documented BRCA1 or BRCA2 germline mutation
  • Patients with known active brain metastases are excluded

Type of study:

Phase I study

Treatment:

Patients receive veliparib orally (PO) twice daily (BID) on days 1-28 and dinaciclib IV over 2 hours on days 8 and 22.

Study site:

Massachusetts
Boston
Dana-Farber Cancer Institute
Contact: Geoffrey Shapiro, MD, PhD: 617-632-4942 geoffrey_shapiro@dfci.harvard.edu

 

Page updated 06/08/13